<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111431</url>
  </required_header>
  <id_info>
    <org_study_id>HR0171401-302</org_study_id>
    <nct_id>NCT05111431</nct_id>
  </id_info>
  <brief_title>A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children</brief_title>
  <official_title>Study on Efficacy and Safety of Dexmedetomidine Hydrochloride Nasal Spray for Preoperative Sedation in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Hengrui Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Hengrui Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine&#xD;
      hydrochloride nasal spray for preoperative sedation in children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Dexmedetomidine hydrochloride nasal spray compared with placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who meet parent-child separation successful</measure>
    <time_frame>within 45 minutes after the beginning of administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects who meet the Ramsay sedation score of 3 at least once within 45 minutes after the beginning of administration</measure>
    <time_frame>within 45 minutes after the beginning of administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who meet parent-child separation successful within 45 minutes after the beginning of administration</measure>
    <time_frame>Within 45 minutes after the beginning of administration</time_frame>
    <description>The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success is defined as a scale of 3 or 4 per item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the beginning of administration to the successful parent-child separation for the first time through study completion，an average of 3 days</measure>
    <time_frame>an average of 3 days</time_frame>
    <description>The FUNK scale is a scale of 1 to 4 for sedation, anxiety, and separation from parents. Separation success is defined as a scale of 3 or 4 per item.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose the Ramsay score is satisfactory at least once within 45 minutes after the beginning of administration</measure>
    <time_frame>Within 45 minutes after the beginning of administration</time_frame>
    <description>Sedation level using the Ramsay scale. Ramsay Satisfaction is defined as a scale of ≥ 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the beginning of administration to the satisfactory Ramsay score for the first time</measure>
    <time_frame>from the beginning of administration to the first successful Ramsay score</time_frame>
    <description>Sedation level using the Ramsay scale. Ramsay Satisfaction is defined as a scale of ≥ 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects whose the UMSS Scale is satisfactory at least once within 45 minutes after the beginning of administration</measure>
    <time_frame>within 45 minutes after the beginning of administration</time_frame>
    <description>Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction is defined as a scale of ≥ 2 .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from the beginning of administration to the satisfactory UMSS score for the first time through study completion，an average of 3 days</measure>
    <time_frame>an average of 3 days</time_frame>
    <description>Sedation level using the University of Michigan Sedation Scale. UMSS satisfaction is defined as a scale of ≥ 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of anesthesia awakening through study completion，an average of 3 days</measure>
    <time_frame>an average of 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">159</enrollment>
  <condition>Preoperative Sedation of Children</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine Hydrochloride Nasal Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine hydrochloride nasal spray blank preparation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Hydrochloride Nasal Spray</intervention_name>
    <description>In the low weight group, the subjects will receive a low dose of dexmedetomidine nasal spray.&#xD;
In the high weight group, the subjects will receive a high dose of dexmedetomidine nasal spray.</description>
    <arm_group_label>Dexmedetomidine Hydrochloride Nasal Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine hydrochloride nasal spray blank preparation</intervention_name>
    <description>In the low weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.&#xD;
In the high weight group, the subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.</description>
    <arm_group_label>Dexmedetomidine hydrochloride nasal spray blank preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide a written informed consent&#xD;
&#xD;
          2. Male or female&#xD;
&#xD;
          3. Subjects requiring elective general anesthesia surgery&#xD;
&#xD;
          4. Conform to the ASA Physical Status Classification&#xD;
&#xD;
          5. Meet the weight standard&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not suitable for nasal spray&#xD;
&#xD;
          2. Pediatric populations requiring special care or court/social welfare supervision&#xD;
&#xD;
          3. Subjects who had been under general anesthesia when they were randomized&#xD;
&#xD;
          4. Subjects with a history of mental illness and a history of cognitive impairment&#xD;
             epilepsy&#xD;
&#xD;
          5. Subjects with cardiovascular disease&#xD;
&#xD;
          6. Subjects whose hemoglobin is below the lower limit of normal&#xD;
&#xD;
          7. Subjects with a history or possibility of a difficult airway&#xD;
&#xD;
          8. Abnormal liver function and/or abnormal renal function&#xD;
&#xD;
          9. Adrenoceptor agonists or antagonists or analgesics were used before randomization&#xD;
&#xD;
         10. Participated in clinical trials (received experimental drugs)&#xD;
&#xD;
         11. History of hypersensitivity to drug ingredients or components&#xD;
&#xD;
         12. Other circumstances that the investigator judged inappropriate for participation in&#xD;
             this clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Liu, M.M</last_name>
    <phone>+0518-82342973</phone>
    <email>Qin.liu@hengrui.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

